Modality
ASO
MOA
C5i
Target
WEE1
Pathway
Tau
NSCLCCeliacRB
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
May 2017
→ May 2026
Phase 2Current
NCT04748316
1,621 pts·NSCLC
2017-05→2026-05·Terminated
1,621 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-111mo awayPh2 Data· NSCLC
2026-11-278mo awayNDA· Celiac
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Termina…
Catalysts
Ph2 Data
2026-05-11 · 1mo away
NSCLC
NDA
2026-11-27 · 8mo away
Celiac
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04748316 | Phase 2 | NSCLC | Terminated | 1621 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| Bemavorutinib | Acadia Pharma | Phase 1/2 | WEE1 | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Talazumab | Zealand Pharma | Phase 1/2 | WEE1 | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C |